During biotherapeutic production, a range of impurities and variants can be generated, including host cell proteins (HCPs). HCPs present a safety risk as they can produce immunogenic responses and may reduce drug efficacy. To meet regulatory criteria, developers must verify that HCPs have been reduced to an acceptable level.
To keep up with the rapidly growing biotherapeutic industry, the large analytical toolkit of techniques for HCP analysis has continued to evolve.
Download this listicle to discover five recent approaches which help to improve the separation and detection of HCPs, using technologies such as:
